Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
| Autor: | Brian G. Petrich, Daved H. Fremont, Hua Pan, Madhav Subramanian, Phyllis I. Hanson, Ju Young Kim, Hae Chul Park, Karen Krchma, Fadi E. Pulous, Carmen M. Halabi, Ashraf-ul Kabir, Jun Wu, Samuel A. Wickline, Dong Hun Lee, Changwon Park, Kyunghee Choi, Xiaoli Wang, Suhyun Kim, Teri Naismith |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Angiogenesis
medicine.medical_treatment High endothelial venules Article Neovascularization Mice Immune system Cell Line Tumor Tumor Microenvironment Medicine Animals Humans Tumor microenvironment Neovascularization Pathologic business.industry Growth factor Endothelial Cells Nuclear Proteins General Medicine Neoplasms Experimental Actin cytoskeleton Tumor progression Cancer research Immunotherapy medicine.symptom business Transcription Factors |
| Zdroj: | Sci Transl Med |
| Popis: | The crosstalk between angiogenesis and immunity within the tumor microenvironment (TME) is critical for tumor prognosis. While pro-angiogenic and immunosuppressive TME promote tumor growth, anti-angiogenic and immune stimulatory TME inhibit tumor progression. Therefore, there is a great interest in achieving vascular normalization to improve drug delivery and enhance anti-tumor immunity. However, anti-vascular endothelial growth factor (VEGF) mechanisms to normalize tumor vessels have offered limited therapeutic efficacies for cancer patients. Herein, we report that Myct1, a direct target of ETV2, was nearly exclusively expressed in endothelial cells. In preclinical mouse tumor models, Myct1 deficiency reduced angiogenesis, enhanced high endothelial venule formation, and promoted an anti-tumor immune environment, leading to restricted tumor progression in Myct1 knockout mice. Analysis of The Cancer Genome Atlas (TCGA) datasets revealed a significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|